000 01555 a2200421 4500
005 20250516003600.0
264 0 _c20110519
008 201105s 0 0 eng d
022 _a1873-5576
024 7 _a10.2174/156800910793357952
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGeis, Nicolas
245 0 0 _aInhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
_h[electronic resource]
260 _bCurrent cancer drug targets
_cDec 2010
300 _a922-31 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aCD55 Antigens
_xchemistry
650 0 4 _aCD59 Antigens
_xchemistry
650 0 4 _aComplement Activation
_xgenetics
650 0 4 _aFlow Cytometry
650 0 4 _aHumans
650 0 4 _aMembrane Cofactor Protein
_xantagonists & inhibitors
650 0 4 _aNeoplasms
_xgenetics
650 0 4 _aRNA, Messenger
_xgenetics
650 0 4 _aRNA, Neoplasm
_xgenetics
650 0 4 _aRNA, Small Interfering
_xgenetics
650 0 4 _aReverse Transcriptase Polymerase Chain Reaction
650 0 4 _aTumor Cells, Cultured
700 1 _aZell, Stefanie
700 1 _aRutz, Renate
700 1 _aLi, Wenhan
700 1 _aGiese, Thomas
700 1 _aMamidi, Srinivas
700 1 _aSchultz, Stefan
700 1 _aKirschfink, Michael
773 0 _tCurrent cancer drug targets
_gvol. 10
_gno. 8
_gp. 922-31
856 4 0 _uhttps://doi.org/10.2174/156800910793357952
_zAvailable from publisher's website
999 _c20208419
_d20208419